Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deborah Thomas

Showing results (111-120 of 155) with videos related to

Pageof 16
Sort By:
Cancer|June 5, 2003
Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinosideGuillermo Garcia-Manero, Moshe Talpaz, Francis J Giles, et al.
Blood|May 29, 2016
Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemiaNicholas J Short, Elias Jabbour, Koji Sasaki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2004
A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemiaFrancis Giles, Deborah Thomas, Guillermo Garcia-Manero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2009
Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatmentWilliam G Wierda, Susan O'Brien, Xuemei Wang, et al.
Cancer|December 15, 2005
A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimensWilliam Wierda, Susan O'brien, Stefan Faderl, et al.
American Journal of Hematology|April 22, 2011
Prediction model for mortality after intracranial hemorrhage in patients with leukemiaFarshid Dayyani, Sarah Schellhorn Mougalian, Kiran Naqvi, et al.
The New England Journal of Medicine|October 6, 2006
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletionAlan List, Gordon Dewald, John Bennett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2005
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemiaMichael J Keating, Susan O'Brien, Maher Albitar, et al.
Cancer|August 28, 2003
Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phaseSusan O'Brien, Francis Giles, Moshe Talpaz, et al.
Clinical Lymphoma & Myeloma|December 16, 2005
T-cell prolymphocytic leukemia: a single-institution experienceFarhad Ravandi, Susan O'Brien, Dan Jones, et al.
Pageof 16

Showing results (111-120 of 155) with videos related to

Sort By:
Pageof 16
Cancer|June 5, 2003
Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinosideGuillermo Garcia-Manero, Moshe Talpaz, Francis J Giles, et al.
Blood|May 29, 2016
Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemiaNicholas J Short, Elias Jabbour, Koji Sasaki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2004
A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemiaFrancis Giles, Deborah Thomas, Guillermo Garcia-Manero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2009
Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatmentWilliam G Wierda, Susan O'Brien, Xuemei Wang, et al.
Cancer|December 15, 2005
A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimensWilliam Wierda, Susan O'brien, Stefan Faderl, et al.
American Journal of Hematology|April 22, 2011
Prediction model for mortality after intracranial hemorrhage in patients with leukemiaFarshid Dayyani, Sarah Schellhorn Mougalian, Kiran Naqvi, et al.
The New England Journal of Medicine|October 6, 2006
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletionAlan List, Gordon Dewald, John Bennett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2005
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemiaMichael J Keating, Susan O'Brien, Maher Albitar, et al.
Cancer|August 28, 2003
Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phaseSusan O'Brien, Francis Giles, Moshe Talpaz, et al.
Clinical Lymphoma & Myeloma|December 16, 2005
T-cell prolymphocytic leukemia: a single-institution experienceFarhad Ravandi, Susan O'Brien, Dan Jones, et al.
Pageof 16